Safety issues in the management of autoimmune hepatitis

Expert Opinion on Drug Safety

Volumn 7, Issue 3, 2008, Pages 319-333

  Czaja, Albert J ^a  

^a Mayo Clinic   (United States)

Author keywords

Autoimmune hepatitis; Azathioprine; Metabolic pathways; Prednisone; Toxicities

Indexed keywords

ALENDRONIC ACID; AZATHIOPRINE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ACNE; ALOPECIA; ARTHRALGIA; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; COUNSELING; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DORSAL HUMP; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ESTHETICS; FACE DISORDER; FACIAL HIRSUTISM; FACIAL ROUNDING; HEMATOLOGIC DISEASE; HIGH RISK POPULATION; HIRSUTISM; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE VILLUS ATROPHY; LEUKOPENIA; LIVER FIBROSIS; LIVER INJURY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MALABSORPTION; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MENTAL INSTABILITY; MONOTHERAPY; NAUSEA; NONHUMAN; OBESITY; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PATIENT SELECTION; REVIEW; SIDE EFFECT; SPINE DISEASE; STRIA; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT DURATION; VERTEBRA COMPRESSION; VOMITING; WEIGHT GAIN; DRUG COMBINATION;

AZATHIOPRINE; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PATIENT SELECTION; PREDNISONE;

EID: 44949148177     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.7.3.319     Document Type: Review

References (134)

1. Montano Loza AJ, Czaja AJ. Current therapy for autoimmune hepatitis. Nat Clin Pract Gastroenterol Hepatol 2007;4:202-14
2. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. QJ Med 1971;40:159-85
3. Soloway RD, Summerskill WHJ, Baggenstoss AM, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33
4. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7
5. Roberts SK, Therneau T, Czaja AJ. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996;110:848-57
6. Czaja AJ, Carpenter HA. Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis. J Hepatol 2004;40:644-50
7. Czaja AJ, Carpenter HA. Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis. Hepatology 2004;39:1631-8
8. Mohamadnejad M, Malekzadeh R, Nasseri-Maghaddam S, et al. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005;50:547-51
9. Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984;4:622-7
10. Czaja AJ, Ammon HV, Summerskill WHJ. Clinical features and prognosis of severe chronic active liver disease (CALD) after corticosteroid-induced remission. Gastroenterology 1980;78:518-23
11. Czaja AJ, Ludwig J, Baggenstoss AH, et al. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981;304:5-9
12. Czaja AJ, Beaver SJ, Shiels MT. Sustained remission following corticosteroid therapy of severe HBsAg-negative chronic active hepatitis. Gastroenterology 1987;92:215-9
13. Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003;23:116-23
14. Czaja AJ, Menon KVN, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-7
15. Hegarty JE, Nouri-Aria KT, Portmann B, et al. Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983;3:685-9
16. Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988;8:781-4
17. Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995;333:958-63
18. Montano-Loza A, Carpenter HA, Czaja AJ. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007;27:507-15
19. Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990;11:1044-9
20. Mistilis SP, Vickers CR, Darroch MH, et al. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985;143:463-5
21. Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987;93:890-3
22. Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994;21:1040-7
23. Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995;36:459-61
24. Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6
25. Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy far autoimmune hepatitis - report of three cases. J Gastroenterol 1997;35:571-8
26. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-3
27. Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998;13:490-5
28. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7
29. Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999;30:1381-6
30. Debray D, Maggiore G, Girardet JP, et al. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatrics 1999;135:111-4
31. Fernandes NF, Redeker AG, Vierling JM, et al. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999;94:241-8
32. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5
33. Malekzadeh R, Nasser-Moghaddam S, Kaviani M-J, et al. Cyclosporin-A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001;46:1321-7
34. Devlin SM, Swain MG, Urbanski SJ, et al. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy. Can J Gastroenterol 2004;18:321-6
35. Aqel BA, Machicao V, Rasser B, et al. Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis. J Clin Gastroenterol 2004;38:805-9
36. Czaja AJ, Carpenter HA. Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease. J Clin Gastroenterol 2005;39:819-25
37. Larsen FS, Vainer B, Eefsen M, et al. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007;13:3232-6
38. Inductivo-Yu I, Adams A, Gish RG, et al. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007;5:799-802
39. Summerskill WHJ, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975;16:876-83
40. Wright SH, Czaja AJ, Katz RS, Soloway RD. Systemic mycosis complicating high dose corticosteroid treatment of chronic active liver disease. Am J Gastroenterol 1980;74:428-32
41. Bongiovanni AM, Eisenmenger WJ. Adrenal cortical metabolism in chronic liver disease. J Clin Endocrinol 1951;11:152-72
42. Bearn AG, Kunkel HG, Slater RJ. The problem of chronic liver disease in young women. Am J Med 1956;21:3-15
43. Willocx RG, Isselbacher KJ. Chronic liver disease in young people. Clinical features and course of thirty-three patients. Am J Med 1961;30:185-95
44. Read AE, Sherlock S, Harrison CV. Active 'juvenile' cirrhosis considered as part of a systemic disease and the effect of corticosteroid therapy. Gut 1963;4:378-93
45. Schalm SW, Summerskill WHJ, Go VLW. Prednisone for chronic active liver disease: pharmacokinetics, including conversion to prednisolone. Gastroenterology 1977;72:910-3
46. Uribe M, Schalm SW, Summerskill WHJ, et al. Oral prednisone for chronic liver disease: dose responses and bioavailability studies. Gut 1978;19:1131-5
47. Uribe M, Summerskill WHJ, Go VLW. Comparative serum prednisone and prednisolone concentrations following administration to patients with chronic active liver disease. Clin Pharmacokinet 1982;7:452-9
48. Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984;6:331-5
49. Lewis GP, Jusko WJ, Burke CW, et al. Prednisone side-effects and serum protein levels: a collaborative study. Lancet 1971;2:778-81
50. Uribe M, Go VLW. Corticosteroid pharmacokinetics in liver disease. Clin Pharmacokinet 1979;4:233-40
51. Kanzler S, Gerken G, Lohr H, et al. Duration of immunosuppressive therapy in autoimmune hepatitis. J Hepatol 2001;34:354-5
52. Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002;35:7-13
53. DePinho RA, Goldberg CS, Lefkowitch JH. Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology 1984;86:162-5
54. Czaja AJ, Carpenter HA. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006;51:968-75
55. Eland IA, Van Puijenbroek EP, Sturkenboom MJ, et al. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol 1999;94:2417-22
56. Bajaj JS, Saeian K, Varma RR, et al. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am J Gastroenterol 2005;100:1121-5
57. Ziegler TR, Fernandez-Estivariz C, Gu LH, et al. Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology 2003;124:1950-7
58. Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 1986;104:651-5
59. Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 1986;90:446-54
60. Bacon BR, Treuhaft WH, Goodman AM. Azathioprine-induced pancytopenia. Occurrence in two patients with connective tissue diseases. Arch Intern Med 1981;141:223-6
61. Jeurissen MEC, Boerbooms AMTH, Van De Putte LBA. Pancytopenia related to azathioprine in rheumatoid arthritis. Ann Rheum Dis 1988;47:503-5
62. Maddocks JL, Lennard L, Amen J, et al. Azathioprine and severe bone marrow depression. Lancet 1986;1:156
63. Ben Ari ZIV, Mehta A, Lennard L, et al. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23:351-4
64. Langley PG, Underhill J, Tredger JM, et al. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37:441-7
65. Heneghan MA, Allan ML, Bornstein JD, et al. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006;45:584-91
66. Rosenkrantz JG, Githens JH, Cox SM, et al. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967;97:387-94
67. Steven MM, Buckley JD, Mackay IR. Pregnancy in chronic active hepatitis. QJ Med 1979;48:519-31
68. Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001;48:97-102
69. Candia L, Marquez J, Espinoza LR. Autoimmune hepatitis and pregnancy: a rheumatologist's dilemma. Sem Arthritis Rheum 2005;35:49-56
70. Uribe M, Chavez-Tapia NC, Mendez-Sanchez N. Pregnancy and autoimmune hepatitis. Ann Hepatol 2006;5:187-9
71. Schramm C, Herkel J, Beuers U, et al. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006;101:556-60
72. Werner M, Bjornsson E, Prytz H, et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breast feeding. Scand J Gastroenterol 2007;42:986-91
73. De Boer NK, Jarbandhan SV, De Graaf P, et al. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006;101:1390-2
74. Penn I. Tumor incidence in allograft recipients. Transplant Proc 1979;11:1047-51
75. Aguilar HI, Burgart LJ, Geller A, et al. Azathioprine-induced lymphoma manifesting as fulminant hepatic failure. Mayo Clin Proc 1997;72:643-5
76. Wang KK, Czaja AJ, Beaver SJ, et al. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989;10:39-43
77. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33
78. Gisbert JP, Gonzalez-Guijarro L, Cara C, et al. Thiopurine methyltransferase activity in patients with autoimmune hepatitis. Med Clin (Barc) 2003;121:481-4
79. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39
80. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7
81. Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73
82. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14
83. Alves S, Prata MJ, Ferreira F, et al. Screening of thiopurine methyl s-transferase mutations by horizontal conformation-sensitive gel electrophoresis. Hum Mutat 2000:15:246-53
84. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8
85. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of esythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651-62
86. Cuffari C, Dassopoulis T, Turnbough L, et al. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-7
87. McLeod HL, Relling MV, Liu Q, et al. Polymorphic thiopurine methyl transferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 1995;85:1897-902
88. Gisbert JP, Gomollon F, Cara C, et al. Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 2007;52:1262-9
89. Tamori A, Shinzaki M, Kosaka S, et al. Thiopurine S-methyltransferase gene polymorphism in Japanese patients with autoimmune liver diseases. Liver Int 2007;27:95-100
90. Schramm C, Kanzler S, Meyer Zum Buschenfelde K-H, et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol 2001;96:1587-91
91. Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006;43:532-8
92. Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral center. J Hepatol 2006;45:575-83
93. Miyake T, Miyaoka H, Abe M, et al. Clinical characteristics of autoimmune hepatitis in older aged patients. Hepatol Res 2006;36:139-42
94. Lebovics E, Schaffner F, Klion EM, et al. Autoimmune chronic active hepatitis in postmenopausal women. Dig Dis Sci 1985;30:824-8
95. Wang KK, Czaja AJ. Prognosis of corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis in postmenopausal women: a retrospective analysis. Gastroenterology 1989;97:1288-93
96. Verslype C, George C, Buchel E, et al. Diagnosis and treatment of autoimmune hepatitis at age 65 and older. Aliment Pharmacol Ther 2005;21:695-9
97. Schalm SW, Ammon HV, Summerskill WHJ. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976;8:221-7
98. Montano-Loza AJ, Carpenter HA, Czaja AJ. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end stage liver disease. Hepatology 2007;46:1138-45
99. Czaja AJ. Treatment strategies in autoimmune hepatitis. Clin Liver Dis 2002;6:799-824
100. Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine. Gastroenterology 1996;110:271-4
101. Sanchez-Urdazpal L, Czaja AJ, Van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15:215-21
102. Varma RR, Michelsohn NH, Borkowf HI, et al. Pregnancy in cirrhotic and noncirrhotic portal hypertension. Obstet Gynecol 1977;50:217-22
103. Nagy S, Bush MC, Berkowitz R, et al. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 2003;102:121-8
104. Whitacre CC, Reingold SC, O'Looney PA. A gender gap in autoimmunity. Science 1999;283:1277-8
105. Buchel E, Van Steenbergen W, Nevens F, et al. Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol 2002;97:3160-5
106. Kogan J, Safadi R, Ashur Y, et al. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis. A study of 68 patients. J Clin Gastroenterol 2002;35:75-81
107. Feld JJ, Dinh H, Arenovich T, et al. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. Hepatology 2005;42:53-62
108. Koretz RL, Lewin KJ, Higgins J, et al. Chronic active hepatitis. Who meets treatment criteria? Dig Dis Sci 1980;25:695-9
109. DeGroote J, Fevery J, Lepoutre L. Long-term follow-up of chronic active hepatitis of moderate severity. Gut 1978;19:510-3
110. Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46:1271-8
111. Cuffari C, Theoret Y, Latour S, et al. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6
112. Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13
113. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-23
114. Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;40:665-70
115. Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15
116. Seela S, Sheela H, Boyer JL. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005;25:734-9
117. Banerjee S, Rahhal R, Bishop WP. Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2006;43:353-6
118. Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007;102:1005-12
119. Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004;40:897-903
120. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007;45:797-805
121. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000;31:864-71
122. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003;124:91-6
123. Ichai P, Duclos-Vallee J-C, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007;13:996-1003
124. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007;13:953-5
125. Czaja AJ, Bianchi FB, Carpenter HA, et al. Treatment challenges and investigational opportunities in autoimmune hepatitis. Hepatology 2005;41:207-15
126. Czaja AJ. Autoimmune hepatitis - Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007;1:113-28
127. Vierling JM, Flores PA. Evolving new therapies of autoimmune hepatitis. Clin Liver Dis 2002;6:825-50
128. Fridkis-Hareli M, Rosloniec EF, Fugger L, et al. Synthetic peptides that inhibit binding of the collagen type II 261-273 epitope to rheumatoid arthritis-associated HLA-DR1 and -DR4 molecules and collagen-specific T-cell responses. Hum Immunol 2000;61:640-50
129. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with and-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117:761-9
130. Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000;119:1461-72
131. Santos ES, Arosemena LR, Raez LE, et al. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int 2006;26:625-9
132. Wardrop RM, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999;48:106-19
133. Schwartz RS. The new immunology - the end of immunosuppressive drug therapy? (editorial). N Engl J Med 1999;340:1754-6
134. Autoimmune liver disease. Action Plan for Liver Disease Research. National Institute of Diabetes and Digestive and Liver Diseases, Bethesda, MD: 2004. [Last accessed 20 January 2006]. Available from: http://www.niddk.nih.gov/fund/divisions/ddn/ldrb/topics.htm